Stock Details
BIIB is Biogen Inc.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 203.29$. Average daily volumn in 3 months 1.11M. Market cap 31.04B



Stock symbol : BIIB. Exchange : NasdaqGS. Currency : USD
Lastest price : 211.93$. Total volume : 2.95M. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Biogen Inc. (BIIB)
Last Price
211.93$
Change
0.55
Volume
2.95M

Previous Close211.38
Open211.38
Day Range207.19-212.71
Bid211.67 x 1k
Ask215.00 x 800
Volume2.95M
Average Volume1.11M
Market Cap31.04B
Beta0.42
52 Week Range187.16-372.12
Trailing P/E21.69
Foward P/E13.25
Dividend (Yield %)N/A
Ex-Dividend DateN/A



Financial Details


According to Biogen Inc.'s financial reports the company's revenue in 2021 were 10.98B an decrease(-23.08%) over the years 2020 revenue that were of 13.44B. In 2021 the company's total earnings were 1.56B while total earnings in 2020 were 4B(-75%).


Loading ...



Organization

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXAB... I, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Market Cap:
31.04B
Revenue:
10.98B
Total Assets:
23.88B
Total Cash:
2.26B



News about "Biogen Inc."

biogen-inc-nasdaqbiib-shares-purchased-by-diversified-trust-co-image

Biogen Inc. (NASDAQ:BIIB) Shares Purchased by Diversified Trust Co

Source from : Defense World - 12 hours ago

Diversified Trust Co lifted its holdings in Biogen Inc. (NASDAQ:BIIB โ€“ Get Rating) by 33.2% in the first quarter, HoldingsChannel reports. The firm owned 1,485 shares of the biotechnology companyโ€™s ...See details»


biogen-inc-nasdaqbiib-shares-sold-by-bowling-portfolio-management-llc-image

Biogen Inc. (NASDAQ:BIIB) Shares Sold by Bowling Portfolio Management LLC

Source from : Defense World - 2 days ago

Bowling Portfolio Management LLC reduced its position in shares of Biogen Inc. (NASDAQ:BIIB โ€“ Get Rating) by 4.2% during the 1st quarter, Holdings Channel.com reports. The firm owned 1,314 shares of ...See details»


Biogen stops clinical trial tracking Aduhelm

Source from : MarketWatch on MSN.com - 1 days ago

Biogen Inc. said in a statement that it stopped a post-marketing clinical trial testing its Alzheimer's disease therapy Aduhelm, citing a Medicare policy that will limit usage of the drug. The company ...See details»


when-the-price-of-biogen-inc-common-stock-biib-talks-people-listen-image

When the Price of Biogen Inc. Common Stock BIIB Talks, People Listen

Source from : news.stocktradersdaily - 1 days ago

Buy BIIB over 195.67 target n/a stop loss @ 195.1. Details; The technical summary data tells us to buy BIIB near 195.67, but there is no curren ...See details»


biogen-pulls-plug-on-aduhelm-real-world-study-on-coverage-woes-image

Biogen pulls plug on Aduhelm real-world study on coverage woes

Source from : Seeking Alpha - 1 days ago

Alzheimer's disease therapy Aduhelm woes seem to continue as the company terminated a study calledย ICARE AD, which was started to collect real-world data on ...See details»


biogen-citing-insurance-challenges-shutters-one-of-its-aduhelm-studies-image

Biogen, citing insurance challenges, shutters one of its Aduhelm studies

Source from : BioPharma Dive - 2 days ago

The company says a recent coverage decision by Medicare has forced it to end an observational trial of the Alzheimer's drug after enrolling just 29 participants.See details»


biogen-secures-tecfidera-patent-in-eu-until-2028-generics-not-likely-image

Biogen Secures Tecfidera Patent in EU Until 2028; Generics Not Likely

Source from : Multiple Sclerosis News Today - 2 days ago

Biogen's new patent for its oral MS medication Tecfidera expires in 2028 โ€“ so generics likely will not enter the European market until then.See details»


biogen-happify-health-partner-to-offer-digital-ms-support-tool-image

Biogen, Happify Health partner to offer digital MS support tool

Source from : Healio - 1 days ago

Biogen and Happify Health have announced a partnership to provide an artificial intelligence-powered digital solution for people with MS called Kopa, which will offer support for patients through ...See details»


the-biogen-foundation-and-community-lab-celebrates-20-years-of-serving-our-communities-image

The Biogen Foundation and Community Lab Celebrates 20 Years of Serving our Communities

Source from : YAHOO!Finance - 11 days ago

The Biogen Foundation has granted $70 million to help underserved communities in advancing science education, health equity, and food securityMore than 61,000 students have benefitted from Biogenโ€™s ...See details»


Biogen Inc. (BIIB) Down 4.8% Since Last Earnings Report: Can It Rebound?

Source from : Nasdaq - 23 days ago

It has been about a month since the last earnings report for Biogen Inc. (BIIB). Shares have lost about 4.8% in that time frame, underperforming the S&P 500. Will the recent negative trend ...See details»


Biogen Inc.: Our New Capsule System Tackles Biopharma ESG Risk Tied to U.S. Drug Pricing and Cost-Effectiveness

Source from : YAHOO!Finance - 12 days ago

Find the latest Biogen Inc. (BIIB) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance ...See details»


biogen-says-bye-to-217m-als-partnership-with-karyopharm-image

Biogen says bye to $217m ALS partnership with Karyopharm

Source from : pharmaphorum - 8 days ago

US biotech Karyopharm loses a $217m partnership with Biogen, which has handed back rights to amyotrophic lateral sclerosis therapy BIIB100 after a phase 1 trial completed ...See details»


Biogen Inc.: European Patent Office Grants Patent Related to TECFIDERA (Dimethyl Fumarate)

Source from : Finanznachrichten - 4 days ago

Patent covers approved dosing regimen for TECFIDERA and expires in 2028 CAMBRIDGE, Mass., June 21, 2022Inc. (Nasdaq: BIIB) today announced that the European Patent Office has granted a patent that ...See details»


learn-to-evaluate-biogen-inc-common-stock-biib-using-the-charts-image

Learn to Evaluate Biogen Inc. Common Stock (BIIB) using the Charts

Source from : news.stocktradersdaily - 11 days ago

This data also tells us to set a stop loss @ 171.33 to protect against excessive loss in case the stock begins to move against the trade. 171.83 is the first level of support below 192.16 , and by ...See details»